Know-How Protection in Pharmaceutical Companies

Four years have passed since the first proposal of the strategic plan Made in China 2025 (MiC 2025). Although China is toning down the public media coverage and official statements regarding the MiC 2025, the plan is still running. Its goals focus on high-tech areas, including the pharmaceutical industry. The MiC 2025 plan sets ambitious… Continue reading Know-How Protection in Pharmaceutical Companies

Stricter Control of Experimental Data in China

In the field of pharmaceutical and chemical substances, inconsistencies in the experimental data of a patent application in China can lead to the doubts on patent’s validity. The Higher People’s Court in Peking has decided in multiple cases that submission of incomplete or false data violates the “quid pro quo” principle in disclosing the patent… Continue reading Stricter Control of Experimental Data in China

Webinar Invitation: Pharma and Biotech in China

Changes in legal framework, successful market entry and IP protection Thursday, 29. January 2019 | 10:00 – 11:00 EST / 16:00 – 17:00 CET China is the world’s second largest market for pharmaceuticals and medical devices. Many Western manufacturers are still reluctant in entering the Chinese market. So far, their reasoning often included non-transparent regulations… Continue reading Webinar Invitation: Pharma and Biotech in China